Forgot your password? If your employer has a site license, create your account to begin using it. Otherwise, please explore our free content subscriptions. Create an account. Enter the email address associated with your account and a temporary password will be sent to you.
Collaboration in Pharma – Today’s Business Imperative · Inova Software
Need help? Contact us at , , or clientservices pharmamedtechbi. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer.
- PharmaShots - Insicive News in 3 Shots | Pharma Biotech MedTech DigiHealth?
- DEALS INSIGHT!
- stage coupon code 2019?
New to online subscriber access? Create your account.
The most trusted and reliable source for analyzing and tracking health care deals. What can a subscription to Strategic Transactions do for you?
News and Events
Sales Inquiries? Email Address Need help?
Name Your Feed. Lower valuations for many companies in the sector has made them more attractive to prospective purchasers. I would say innovation in biopharmaceutical drug development and discovery has been coming from the biotech industry for quite some time. Some of this ferment of activity reflected a highly beneficial investment environment since the end of the financial crisis after the Federal Reserve, the US central bank, decided to add liquidity to the system, Mr Elms suggested.
Another force driving acquisitions may be the increasingly platform-driven nature of drug discovery, as pharma companies look to shore up their position against rivals by rapidly acquiring a key technology. However, despite this demonstration of what can transpire when a company is acquired before a key medicine has proven its worth, seems certain to see big pharma continuing its biotech tear. Speaking at JPMorgan this week, Emma Walmsley, chief executive of GSK, indicated she, for one, is far from being done with dealmaking, saying she would look to buy early-stage assets and partner with companies.
The recent flurry of dealmaking is not the only sign that the boundary between large pharmaceutical companies and the biotechnology sector is becoming increasingly porous. Mark Mallon, who held a number of senior executive positions in 24 years at AstraZeneca, will become chief executive of Ironwood Pharmaceuticals which specialises in gastro-intestinal treatments. Meanwhile, after six years as president of AstraZeneca subsidiary MedImmune, Bahija Jallal was this month appointed chief executive of Immunocore which develops biological drugs to treat cancer, infectious diseases and autoimmune diseases.
Europe, Middle East & Africa
Manage cookies. Make sense of a disrupted world Explore the new agenda. Pharmaceuticals sector. Experimental feature. Listen to this article Play audio for this article Pause What was mispronounced? Optional: help us by adding the time.
Related pharma collaboration deals
Copyright 2019 - All Right Reserved